Associated Papers
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients.
Bonifacio M et al.
Annals of Hematology, 2019
Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR et al.
Oncogene, 2019
Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
Sun C et al.
Chinese Medical Journal, 2016
Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
Mehrotra M et al.
American Journal of Clinical Pathology, 2015
The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y et al.
American Journal of Clinical Pathology, 2015
Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring.
Chi J et al.
Annals of Hematology, 2015
Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A et al.
Leukemia, 2014
Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients.
Qiao C et al.
Haematologica, 2014
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
Tefferi A et al.
Leukemia, 2014
Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.
Chi J et al.
Leukemia, 2014
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J et al.
The New England Journal of Medicine, 2013
Select a paper to view details